All In Biotech

Drug Trial Radar · NCT07722312

S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

A Phase 1/2, Dose Optimization and Dose Expansion, Multicenter, Open-label Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Menin Inhibitor S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Patients With Relapsed or Refractory Acute Myeloid Leukemia With NPM1c Mutation

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Feb 1, 2027

Primary completion

Aug 11, 2029

Study completion Aug 25, 2030

Sponsor

Lead sponsor
ServierIndustry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to establish the efficacy, safety, and tolerability of S243249 and to establish the recommended phase 2 dose (RP2D) of S243249 monotherapy in participants with relapsed/refractory (R/R) acute leukemia with select mutations. Phase 1 dose optimization will determine the RP2D to be used in Phase 2 dose expansion. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up period and a long-term follow-up period. Participants may undergo blood tests, electrocardiogram (ECG), bone marrow aspirations, vital sign checks, questionnaires, and physical exams.

Conditions

  • Relapsed or Refractory Acute Leukemia
  • Relapsed or Refractory Acute Myeloid Leukemia

Interventions

  • S243249 600mgDrug

    Taken twice daily by mouth

  • S243249 400mgDrug

    Taken twice daily by mouth

  • S243249 450mgDrug

    Taken twice daily by mouth

  • S243249 300mgDrug

    Taken twice daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Adverse Events (AEs)Time frame: Through Safety Follow-up (Approximately 3 years)
  2. Severity of AEsTime frame: Through Safety Follow-up (Approximately 3 years)
  3. Number of Serious Adverse Events (SAEs)Time frame: Through Safety Follow-up (Approximately 3 years)
  4. Number of changes in laboratory valuesTime frame: Through Safety Follow-up (Approximately 3 years)
  5. Number of changes in electrocardiogram (ECG)Time frame: Through Safety Follow-up (Approximately 3 years)
  6. Number of changes in vital signsTime frame: Through Safety Follow-up (Approximately 3 years)
  7. Number of AEs leading to dose interruptionTime frame: Through Safety Follow-up (Approximately 3 years)
  8. Number of AEs leading to dose modificationTime frame: Through Safety Follow-up (Approximately 3 years)
  9. Number of AEs leading to dose delaysTime frame: Through Safety Follow-up (Approximately 3 years)
  10. Number of AEs leading to permanent treatment discontinuationTime frame: Through Safety Follow-up (Approximately 3 years)
  11. Complete remission (CR) + Complete remission with partial recovery of hematology (CRh) rateTime frame: Through Long-term Follow-up (Approximately 5 years)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.